Due to essential maintenance and update work, this website will not be accessible from 8:30am to 5:30pm on 29 April 2017. We are grateful for your patience.
|| The Adacolumn is an adsorptive
type extracorporeal leukocyte apheresis device. The apheresis
column is filled with specially designed cellulose acetate
beads as the adsorptive carriers. Analyses of the blood emerging
from the column have revealed that the carriers selectively
adsorb granulocytes and monocytes / macrophages; lymphocytes
are not significantly adsorbed. Therefore, the Adacolumn
is for selective leukocyte apheresis.
of Granulocytes, Monocytes / Macrophages with Tissue Injury
Inflammatory bowel disease (IBD) like ulcerative
colitis (UC) is an autoimmune disorder, patients
with UC are likely to have elevated and activated
granulocytes. Active UC is frequently associated
with infiltration of large number of granulocytes
and macrophages into the bowel mucosa. The
infiltrated leukocytes can release degradative
enzymes, oxygen derivatives and proinflammatory
substances that can cause bowel injury and
promote further inflammation. It is believed
that much of the watery diarrhea seen in
severe IBD is a result of injury to the absorptive
epithelium, thus making these cells incapable
of absorbing adequate water. These understandings
have led some experts to believe that management
of excess or activated granulocytes and monocytes
/ macrophages by apheresis should be a novel
new strategy to promote remission of active
This view was supported by a recent multicenter
clinical trial that showed Adacolumn apheresis
produced remission in a large fraction of
patients with severe active UC together with
a remarkable safety record. In reality, with
Adacolumn apheresis, physicians achieved
remission of UC that had been difficult to
realize with conventional medications.
Approval of Adacolumn Medical Device in Japan
In Japan, results from
the multicenter clinical trial in patients
with active UC mentioned above provided
the required safety and efficacy data
for the approval of Adacolumn by the
Japan Ministry of Health and Welfare
as a medical device for the treatment
of patients with active UC. Approval
No 21100BZZ00687000. Hence, currently
Adacolumn is available on the market
throughout Japan and is being used
for treating active UC.
Similarly, in subsequent years, the Adacolumn was introduced into the national health reimbursement scheme for the treatment of patients with active Crohn's disease, and pustular psoriasis, which is expressed as a neutrophilic dermatosis.
Find Out More About
- Adacolumn is a selective leukocyte
- Adacolumn apheresis is very effective for
active ulcerative colitis.
- Adacolumn has an excellent safety record.
- Adacolumn apheresis is associated
burden on the patient.
- Adacolumn apheresis improves
of Life and lowers medical